SCHEMBL24178792

SCHEMBL24178792

CCCCCCCCCCCCC(CCCCCCCCCC)COC(OCC(CCCCCCCCCC)CCCCCCCCCCCC)C(C)CC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.42
PRSS1 P07477 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36
OPRM1 P35372 1/20 0.35
CYP3A4 P08684 4/20 0.35
SMPD1 P17405 3/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SPHK1 Q9NYA1 1/20 0.34
ALDH1A1 P00352 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
TSHR P16473 2/20 0.33
ATM Q13315 1/20 0.33
ADH1B P00325 1/20 0.32
ADH1C P00326 1/20 0.32
ADH1A P07327 1/20 0.32
ADH4 P08319 1/20 0.32
ADH7 P40394 1/20 0.32
DNM1 Q05193 1/20 0.32
ACE2 Q9BYF1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24178865 0.89 LMNA (0.42) LMNAPRSS1PRSS2PRSS3OPRM1
SCHEMBL5186405 0.80 LMNA (0.45) LMNAPRSS1PRSS2PRSS3OPRM1
SCHEMBL24178673 0.79 LMNA (0.41) LMNAPRSS1PRSS2PRSS3CYP3A4
SCHEMBL10483854 0.76 LMNA (0.50) LMNAPRSS1PRSS2PRSS3OPRM1
SCHEMBL18327084 0.75 LMNA (0.48) LMNAPRSS1PRSS2PRSS3OPRM1
SCHEMBL18327086 0.75 LMNA (0.48) LMNAPRSS1PRSS2PRSS3OPRM1
SCHEMBL9438365 0.74 LMNA (0.43) LMNAPRSS1PRSS2PRSS3OPRM1
SCHEMBL9438205 0.74 LMNA (0.43) LMNAPRSS1PRSS2PRSS3OPRM1
SCHEMBL5161833 0.74 LMNA (0.43) LMNAPRSS1PRSS2PRSS3OPRM1
SCHEMBL12809112 0.74 LMNA (0.48) LMNAPRSS1PRSS2PRSS3OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3883913-B1 PROCESS FOR MAKING ETHERS VIA ENOL ETHERS BP PLC (GB) 2023-11-01 EP disclosed
US-11787760-B2 Process for making ethers via enol ethers BP P.L.C. (GB) 2023-10-17 US disclosed
US-11787760-B2 Process for making ethers via enol ethers BP P.L.C. (GB) 2023-10-17 US disclosed
US-20220002220-A1 Process for Making Ethers via Enol Ethers BP P.L.C. (GB) 2022-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787760-B2 Process for making ethers via enol ethers ELOVL5, ELOVL1, ELOVL3 LMNA 1249/4885PRSS1 4317/4885PRSS2 3352/4885
US-20220002220-A1 Process for Making Ethers via Enol Ethers ELOVL5, ELOVL1, ELOVL3 LMNA 1249/4885PRSS1 4317/4885PRSS2 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.